Small Molecules

11 Jan 2007 New England Journal of Medicine Reports Aegerion's Lead Compound Reduces LDL By 51% in Patients With a Severe Form of Hypercholesterolemia
11 Jan 2007 Icagen Provides Update on Pain Program Including Its SCN9A Sodium Channel Program
10 Jan 2007 Xytis Begins Phase II Clinical Study With Anatibant (XY2405) For Traumatic Brain Injury
10 Jan 2007 Biogen Idec Initiates Phase III Clinical Program Of Oral Compound BG-12 For Multiple Sclerosis
10 Jan 2007 ZIOPHARM Initiates ZIO-101 Phase II Study in Hematological Cancers
10 Jan 2007 Anthera Receives IND Approval from FDA to begin phase 2 “IMPACTS” trial with A-001 for prevention of acute chest syndrome in patients with sickle cell disease
09 Jan 2007 Protherics submits DigiFab(TM) New Drug Submission in Canada
09 Jan 2007 XenoPort Announces Advancements in Clinical Development Programs
09 Jan 2007 Xytis merges and raises $24.5M
09 Jan 2007 Neurocrine Biosciences Announces Positive Results From Second Phase II Study With Its Orally Active GnRH Receptor Antagonist in Endometriosis
09 Jan 2007 AEterna Zentaris Initiates Phase 1 Trial for ZEN-012, a new small molecule oral anti-cancer drug - IND accepted by FDA
09 Jan 2007 Myriad Genetics Announces Results of Phase 2 Prostate Cancer Trial
09 Jan 2007 Cephalon Announces Positive Results from Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
09 Jan 2007 Incyte to Report Positive Preliminary Clinical Results from HIV and Diabetes Programs and Highlight Progress in Several Drug Development Programs at the 25th JPMorgan Healthcare Conference
09 Jan 2007 The Medicines Company's Cleviprex(TM) (Clevidipine) Phase III Safety Trials Meet Pre-Specified Objectives
09 Jan 2007 Anesiva Announces Clinical Plan for Pivotal Testing of 4975, Long-Acting Pain Candidate
09 Jan 2007 deCODE Advancing Lead Product Development Programs
09 Jan 2007 Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patients With Peripheral T-cell Lymphoma
09 Jan 2007 Quatrx Pharmaceuticals Reports Positive Results From A Phase 2 Trial Of Fispemifene
09 Jan 2007 Xanthus Receives Orphan Drug Designation of Xanafide for the Treatment Of AML
09 Jan 2007 ProEthic Pharmaceuticals Announces Positive Phase III Clinical Trial Results for Fast-Acting Migraine Product Candidate
09 Jan 2007 Targacept Initiates Phase I Clinical Trial of TC-2216
09 Jan 2007 TaiGen Initiates Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
09 Jan 2007 Rigel Announces Initiation of Phase II Study Evaluating R788 in Immune Thrombocytopenic Purpura (ITP)
09 Jan 2007 Horizon Therapeutics Announces Special Protocol Assessment With Fda For Phase 3 Trial Program

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up